Abstract
Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.
| Original language | English |
|---|---|
| Pages (from-to) | 503-507 |
| Number of pages | 5 |
| Journal | The Lancet |
| Volume | 299 |
| Issue number | 7749 |
| DOIs | |
| State | Published - Mar 4 1972 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN. / Gallagher, John Christopher G.; Nordin, B. E C.
In: The Lancet, Vol. 299, No. 7749, 04.03.1972, p. 503-507.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN
AU - Gallagher, John Christopher G.
AU - Nordin, B. E C
PY - 1972/3/4
Y1 - 1972/3/4
N2 - Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.
AB - Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.
UR - http://www.scopus.com/inward/record.url?scp=0015493551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015493551&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(72)90173-0
DO - 10.1016/S0140-6736(72)90173-0
M3 - Article
VL - 299
SP - 503
EP - 507
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 7749
ER -